Opinion

Home Opinion

The next big thing: How technology will transform supermarkets (again)

by
As more people shop for groceries and household staples online, brick-and-mortar supermarkets are likely to become a lot less "super," downsizing to specialty markets.

Site plan covenants should mean something — or why bother?

by
The planning board is considering negating covenants signed by a property owner just 60 days before he applied to change those covenants.

A local’s tips for tourists: How not to wear out your welcome

by
Enjoy our hometown. We make it nice for you so please return the favor and make it nice for us to have you here and want you to come back.

Greg Blass With U.S. research and regulation nearly nonexistent, we must look abroad for information on dangers of cell phone use

by
Dangers from radio frequency waves are real, especially for children and teens.

Suffolk Closeup We must ‘listen to the cry of the Earth’

by
It’s critical for the world to work together to try to stop what is happening.

Letter to the Editor Town board made right call on status of Oak Hills roads

by
Oak Hills resident: Determining that the roads in Oak Hills are 'public highways by use' was the correct decision

Greg Blass How the Suffolk DA came to be the highest-paid elected official in the county — and what you can...

by
The County Legislature long ago gave up control over the district attorney's pay, which is set by the same state commission that sets the salaries of state judges and state legislators.

On DACA, the Dream Act and immigration: statement by Rep. Lee Zeldin

by
Statement issued by Rep. Lee Zeldin on Sept. 5, 2017 in response to President Donald Trump's decision to rescind the Deferred Action for Childhood Arrivals executive order issued by Barack Obama.

Greg Blass Unhappy at work? You’re not alone

by
A recently released study of 3,000 US workers shows that a majority of Americans are unhappy in the workplace.

Suffolk Closeup Here’s hoping ‘anti-vaxxer’ hysteria doesn’t kill new Lyme vaccnine

by
A second Lyme vaccine is in clinical trials under an expedited review by the FDA. An earlier vaccine, approved in 1998, was pulled from the market after a class-action lawsuit a year later claiming the vaccine caused arthritis.